RESEARCH TRIANGLE PARK, N.C. - September 2, 1998 - Quintiles Transnational Corp. (Nasdaq: QTRN) today announced the opening of an office in Israel, expanding its ability to provide a full range of pharmaceutical development services in that country.
Located near Tel Aviv, the office provides clinical trial management, clinical monitoring, regulatory affairs, strategic consulting, pharmacoeconomic analysis and other services to pharmaceutical, biotechnology and medical device companies.
Israel’s world-renowned hospitals and leading therapeutic experts are at the forefront of innovations in drug development,” said Ludo Reynders, Ph.D., Chief Executive Officer of Quintiles Contract Research Organization (CRO) service group. “We believe that our customers will benefit from Quintiles Israel’s strong relationships with leading clinical investigators, healthcare institutions and regulatory authorities.”
About 1,100 clinical trials are conducted in Israel annually, with approximately 60 percent of those being Phase II-IV pharmaceutical studies, 25 percent surveys (such as quality-of-life surveys) and 15 percent medical device studies, according to Israeli health officials.
The Israel office, with 17 employees, is headed by Avi Livnat, Ph.D., General Manager and Country Manager. The address is Kibbutz Shefayim 60990, Israel. Telephone: +972 9 970 8090. Fax: +972 9 970 8099.
Quintiles Transnational Corp. is the market leader in providing full-service contract research, sales and marketing, healthcare policy consulting and health information management services to the worldwide pharmaceutical, biotechnology, medical device and healthcare industries. Quintiles is headquartered near Research Triangle Park, North Carolina. With 13,000 employees worldwide and offices in 29 countries, Quintiles operates through specialized work groups dedicated to meeting customers’ individual needs.